Clinical trial
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to…
NCT00308581 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00308581 |
|---|---|
| Title | Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab |
| Official title | Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological, Other |
| Interventions | Certolizumab pegol, Placebo |
| Enrollment | 539 |
| Start date | Apr 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Mar 29, 2006 |
| Last update posted | Aug 7, 2018 |
| Countries | Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland and 2 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: